MX2009005921A - Formulacion en polvo del valganciclovir. - Google Patents
Formulacion en polvo del valganciclovir.Info
- Publication number
- MX2009005921A MX2009005921A MX2009005921A MX2009005921A MX2009005921A MX 2009005921 A MX2009005921 A MX 2009005921A MX 2009005921 A MX2009005921 A MX 2009005921A MX 2009005921 A MX2009005921 A MX 2009005921A MX 2009005921 A MX2009005921 A MX 2009005921A
- Authority
- MX
- Mexico
- Prior art keywords
- valganciclovir
- powder formulation
- dosage forms
- pharmaceutical dosage
- cytomegalovirus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
La presente invención proporciona nuevas formas farmacéuticas sólidas de dosificación de valganciclovir clorhidrato para la administración oral, después de haberse constituido en agua. Estas nuevas formas farmacéuticas de dosificación son útiles para el tratamiento o control de virus, tales como el virus herpes simple y el citomegalovirus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87463406P | 2006-12-13 | 2006-12-13 | |
PCT/EP2007/063151 WO2008071573A2 (en) | 2006-12-13 | 2007-12-03 | Powder formulation for valganciclovir |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009005921A true MX2009005921A (es) | 2009-06-17 |
Family
ID=39410167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009005921A MX2009005921A (es) | 2006-12-13 | 2007-12-03 | Formulacion en polvo del valganciclovir. |
Country Status (31)
Country | Link |
---|---|
US (6) | US20080146591A1 (es) |
EP (1) | EP2101733B1 (es) |
JP (1) | JP5111517B2 (es) |
KR (1) | KR101116553B1 (es) |
CN (1) | CN101541310B (es) |
AR (1) | AR065541A1 (es) |
AU (1) | AU2007332640B2 (es) |
BR (1) | BRPI0720118B8 (es) |
CA (1) | CA2671470C (es) |
CL (1) | CL2007003564A1 (es) |
CO (1) | CO6220902A2 (es) |
CR (1) | CR10822A (es) |
DK (1) | DK2101733T3 (es) |
ES (1) | ES2391912T3 (es) |
HR (1) | HRP20121033T1 (es) |
IL (1) | IL198854A (es) |
MA (1) | MA31280B1 (es) |
MX (1) | MX2009005921A (es) |
MY (1) | MY152540A (es) |
NO (1) | NO339838B1 (es) |
NZ (1) | NZ577179A (es) |
PE (1) | PE20081578A1 (es) |
PL (1) | PL2101733T3 (es) |
PT (1) | PT2101733E (es) |
RS (1) | RS52457B (es) |
RU (1) | RU2440118C2 (es) |
SI (1) | SI2101733T1 (es) |
TW (1) | TWI341730B (es) |
UA (1) | UA93599C2 (es) |
WO (1) | WO2008071573A2 (es) |
ZA (1) | ZA200903840B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853222B2 (en) * | 2008-03-07 | 2014-10-07 | Ray W. Exley | Treatment of herpes virus related diseases |
CN102048677B (zh) * | 2009-11-09 | 2014-03-05 | 杭州赛利药物研究所有限公司 | 一种盐酸缬更昔洛韦固体制剂及其制备方法 |
US20110245154A1 (en) | 2010-03-11 | 2011-10-06 | Hemaquest Pharmaceuticals, Inc. | Methods and Compositions for Treating Viral or Virally-Induced Conditions |
IN2014MN02105A (es) * | 2012-04-20 | 2015-09-11 | Annji Pharm Co Ltd | |
RU2015132902A (ru) | 2013-01-07 | 2017-02-09 | Сам-А Фарм. Ко., Лтд. | Новый быстрорастворимый состав гранул с улучшенной растворимостью |
EP3027215B1 (en) * | 2013-08-02 | 2017-05-03 | Ali Raif Ilaç Sanayi ve Ticaret Anonim Sirketi | Powder formulation of valganciclovir |
CN104055746B (zh) * | 2014-07-12 | 2017-06-30 | 河北仁合益康药业有限公司 | 一种盐酸缬更昔洛韦包衣片剂组合物 |
RU2720805C1 (ru) * | 2019-05-22 | 2020-05-13 | Общество с ограниченной ответственностью "Трейдсервис" | Фармацевтическая композиция валганцикловира |
KR20220034736A (ko) | 2019-05-31 | 2022-03-18 | 비락타 서브시디어리 인크. | 히스톤 데아세틸라제 억제제를 사용하여 바이러스 관련 암을 치료하는 방법 |
CN110613718A (zh) * | 2019-09-19 | 2019-12-27 | 湖北科益药业股份有限公司 | 一种缬更昔洛韦组合物 |
CN110934823B (zh) * | 2019-12-27 | 2022-03-01 | 湖北康源药业有限公司 | 一种盐酸缬更昔洛韦口服溶液及制备方法 |
WO2021161317A1 (en) * | 2020-02-12 | 2021-08-19 | Cts Chemical Industries Ltd. | Stable pharmaceutical compositions comprising valgancyclovir and uses thereof |
CN114028347B (zh) * | 2021-11-30 | 2023-05-12 | 海南皇隆制药股份有限公司 | 注射用帕瑞昔布钠及其制备方法 |
CN115569113B (zh) * | 2022-09-19 | 2023-11-10 | 江苏汉晨药业有限公司 | 一种盐酸缬更昔洛韦口服溶液 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR880002139B1 (ko) | 1983-04-08 | 1988-10-17 | 베링거 인겔하임 리미티드 | 경구 투여용 정제의 제조방법 |
US5840891A (en) | 1994-07-28 | 1998-11-24 | Syntex (U.S.A.) Inc. | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative |
US5840890A (en) | 1996-01-26 | 1998-11-24 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
JP2001518493A (ja) * | 1997-10-03 | 2001-10-16 | スミスクライン・ビーチャム・コーポレイション | 炭酸リチウムの放出制御性固体投与形 |
US6221917B1 (en) * | 1997-12-30 | 2001-04-24 | American Home Products Corporation | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
CA2244097A1 (en) * | 1998-08-21 | 2000-02-21 | Bernard Charles Sherman | Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid |
US20020143058A1 (en) * | 2001-01-24 | 2002-10-03 | Taro Pharmaceutical Inductries Ltd. | Process for preparing non-hygroscopic sodium valproate composition |
EP1459739B1 (en) | 2003-03-19 | 2008-01-02 | The Jordanian Pharmaceutical Manufacturing Co. Ltd. | Non-hygroscopic pharmaceutical compositions containing non-hydrated quinoline carboxylic acids |
US20070129385A1 (en) * | 2003-08-28 | 2007-06-07 | Sharma Mukesh K | Amorphous valganciclovir hydrochloride |
ATE403418T1 (de) * | 2004-03-10 | 2008-08-15 | Ranbaxy Lab Ltd | Verfahren zur herstellung von festen dosierformen von amorphem valganciclovir-hydrochlorid |
CN102198273A (zh) | 2005-08-22 | 2011-09-28 | 诺瓦提斯公司 | 包含pH依赖性药物、pH调节剂和阻滞剂的药物组合物 |
-
2007
- 2007-12-03 JP JP2009540707A patent/JP5111517B2/ja active Active
- 2007-12-03 PT PT07847662T patent/PT2101733E/pt unknown
- 2007-12-03 EP EP07847662A patent/EP2101733B1/en active Active
- 2007-12-03 MX MX2009005921A patent/MX2009005921A/es active IP Right Grant
- 2007-12-03 CN CN2007800443008A patent/CN101541310B/zh active Active
- 2007-12-03 KR KR1020097014059A patent/KR101116553B1/ko active IP Right Grant
- 2007-12-03 BR BRPI0720118A patent/BRPI0720118B8/pt active IP Right Grant
- 2007-12-03 DK DK07847662.9T patent/DK2101733T3/da active
- 2007-12-03 WO PCT/EP2007/063151 patent/WO2008071573A2/en active Application Filing
- 2007-12-03 CA CA2671470A patent/CA2671470C/en active Active
- 2007-12-03 MY MYPI20092409 patent/MY152540A/en unknown
- 2007-12-03 AU AU2007332640A patent/AU2007332640B2/en active Active
- 2007-12-03 RS RS20120429A patent/RS52457B/en unknown
- 2007-12-03 ES ES07847662T patent/ES2391912T3/es active Active
- 2007-12-03 RU RU2009126616/15A patent/RU2440118C2/ru active
- 2007-12-03 NZ NZ577179A patent/NZ577179A/en unknown
- 2007-12-03 PL PL07847662T patent/PL2101733T3/pl unknown
- 2007-12-03 SI SI200731076T patent/SI2101733T1/sl unknown
- 2007-12-03 UA UAA200907074A patent/UA93599C2/ru unknown
- 2007-12-10 CL CL200703564A patent/CL2007003564A1/es unknown
- 2007-12-11 AR ARP070105524A patent/AR065541A1/es not_active Application Discontinuation
- 2007-12-11 US US12/001,290 patent/US20080146591A1/en not_active Abandoned
- 2007-12-11 TW TW096147281A patent/TWI341730B/zh active
- 2007-12-12 PE PE2007001774A patent/PE20081578A1/es not_active Application Discontinuation
-
2009
- 2009-05-20 IL IL198854A patent/IL198854A/en active IP Right Grant
- 2009-05-21 CR CR10822A patent/CR10822A/es unknown
- 2009-05-22 CO CO09053156A patent/CO6220902A2/es not_active Application Discontinuation
- 2009-06-02 ZA ZA200903840A patent/ZA200903840B/xx unknown
- 2009-06-05 MA MA31956A patent/MA31280B1/fr unknown
- 2009-06-11 NO NO20092254A patent/NO339838B1/no not_active IP Right Cessation
-
2012
- 2012-12-14 HR HRP20121033TT patent/HRP20121033T1/hr unknown
-
2013
- 2013-02-05 US US13/759,348 patent/US8889109B2/en active Active
-
2014
- 2014-10-31 US US14/529,839 patent/US9642911B2/en active Active
-
2017
- 2017-04-05 US US15/479,544 patent/US20170266286A1/en not_active Abandoned
- 2017-12-19 US US15/846,991 patent/US20180153998A1/en not_active Abandoned
-
2018
- 2018-12-19 US US16/225,433 patent/US11185588B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY152540A (en) | Powder formulation for valganciclovir | |
MY179392A (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
IL199152A (en) | Annals 2 - (piperidine-4-ram) -4-phenoxy or phenylamino-pyrimidine, containing and containing pharmaceutical preparations for the preparation of viral infections | |
WO2012078593A3 (en) | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis | |
MY141025A (en) | Dose forms | |
WO2007149406A3 (en) | Modified coagulation factor ix polypeptides and use thereof for treatment | |
MX2010002318A (es) | Derivados azaindol 2,3-sustituidos para tratar infecciones virales. | |
IL192763A (en) | History of pyrimidine, preparations containing them and used in the preparation of cancer drugs | |
IL206296A (en) | History of aminopyrazole, and their medicinal products and their use in the preparation of drugs for the prevention and treatment of diseases | |
IL195142A (en) | Processed arylaimidazolone and triazolone, their preparation process, pharmaceutical preparations containing them for the treatment or prevention of diseases | |
IN2012DN02735A (es) | ||
IN2012DN02730A (es) | ||
IN2012DN00754A (es) | ||
EP2056818A4 (en) | COMPOSITIONS AND METHODS FOR NEUROPROTECTION | |
UA92000C2 (en) | 1-benzylindole-2-carboxamide derivatives | |
MX2009014235A (es) | 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso. | |
NO20081844L (no) | Terapeutiske forbindelser | |
UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
SG10201501376XA (en) | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | |
WO2011160024A3 (en) | Compounds useful as antiviral agents, compositions, and methods of use | |
WO2009114461A3 (en) | Angiotensin (1-7) dosage forms and uses thereof | |
MX2012006430A (es) | Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide. | |
IL210386A (en) | Indole history, their medicinal preparations, and their use in the preparation of drugs for the treatment or prevention of neurodegenerative diseases | |
WO2008004100A9 (en) | Therapeutic compounds | |
IL192454A (en) | Solid Pharmaceuticals Containing S-Adenosylmethionine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |